(Press-News.org) A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montréal (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.
AID is a B-lymphocyte enzyme that creates deliberate mutations in the DNA encoding antibodies, which helps produce an appropriate immune response. However, inappropriate expression of AID can also have harmful effects and lead to certain oncogenic (cancer-causing) mutations. When found in a tumour, uncontrolled levels of AID could increase the rate of gene mutation and, in turn, accelerate the progression of the disease.
"In studying the regulation of AID, we attempted to understand what restricts its access to the cell's nucleus," explains Alexandre Orthwein, doctoral student in Dr. Di Noia's research unit and first author of this study. "If we could control that aspect, we could prevent AID's negative mutating effects. We then discovered that Hsp90, one of the most abundant and vital proteins found in cells, stabilizes AID in the cytoplasm. Cytoplasmic AID is in fact in a dynamic equilibrium regulated by Hsp90."
By stabilizing AID, Hsp90 determines the enzyme's overall expression levels, which correlate with the extent of its physiological functions. Hence, Hsp90 assists AID-mediated antibody diversification. A number of Hsp90 inhibitors being commercially available, the researchers found that Hsp90 inhibition destabilizes AID, thus resulting in a proportional reduction in antibody gene diversification. Moreover, since AID levels also correlate with its pathological side effects, Hsp90 inhibition prevents uncontrolled off-target mutation by AID.
"We showed that inhibiting Hsp90 with known drugs, which are also currently used in clinical trials for the treatment of certain cancers, significantly reduces the amount of AID and, consequently, prevents this enzyme's undesired activity on DNA," adds Dr. Di Noia. "This regulatory mechanism determines the functional levels of AID in normal B cells and B cell lymphoma lines. So, Hsp90 inhibition provides the first pharmacological means to regulate AID expression and activity, which could be relevant for the therapy of some types of lymphoma and leukemia."
Dr. Di Noia, along with the IRCM's Technology Transfer Office, is currently taking the necessary steps to patent the proposed application of the Hsp90 inhibitors with the Canadian Intellectual Property Office (CIPO) and the United States Patent and Trademark Office (USPTO). These patent applications, promoted and commercialized by Univalor, cover the use of the AID biomarker in the selection of a cancer-fighting therapy. In the context of this technology, the treatment using an Hsp90 inhibitor targets tumours expressing AID, and consists of the administration of predetermined doses of the inhibitor in accordance with the expression levels of AID in the tumours.
According to The Leukemia & Lymphoma Society of Canada, one person is diagnosed with a blood cancer every four minutes and someone dies from a blood cancer every 10 minutes. This statistic represents over 54,000 people per year. In 2010, about 628,415 people are living with lymphoma or are in remission.
INFORMATION:
This research project was supported by the Canadian Institutes of Health Research (CIHR). "CIHR is proud to support the type of innovative research that Dr. Javier Marcelo Di Noia and his team are engaging in," says Dr. Morag Park, Scientific Director for CIHR's Institute of Cancer Research. "An understanding of the mechanisms that regulate activation-induced deaminase by heat shock protein 90 (Hsp90) will provide potential new therapies to treat some types of leukemia and lymphoma." The project also received support from the Cancer Research Society (CRS) and the Canada Research Chair program. In addition, Alexandre Orthwein holds a Cole Foundation doctoral fellowship.
Other researchers contributed to the study, including Anne-Marie Patenaude, research assistant in Dr. Di Noia's laboratory, El Bachir Affar from the Hôpital Maisonneuve-Rosemont, Alain Lamarre from the INRS-Institut Armand-Frappier research centre, and Jason C. Young from McGill University.
For more information, please refer to the online article summary published by The Journal of Experimental Medicine. The print publication will be available on November 22, 2010.
A discovery could be important for the therapy of lymphoma and leukemia
The IRCM's Dr. Javier M. Di Noia identifies a mechanism regulating activation-induced deaminase
2010-11-02
ELSE PRESS RELEASES FROM THIS DATE:
Research explores lung cancer among pediatric cancer patients
2010-11-02
Because primary lung adenocarcinoma is exceedingly rare in the pediatric population, it is difficult to properly classify certain lung tumors in children and adolescents. While anecdotal reports of pediatric patients with lung cancer lesions exist, little research has been conducted to link the disease in children to similar pulmonary malignancies in adults. Through an assessment of clinical, tissue-based and molecular data for pediatric lung cancer, research published in the November edition of the Journal of Thoracic Oncology determined that pulmonary lesions found in ...
VIMS scientists help solve mystery of 'alien pod'
2010-11-02
Tracy Collier, an employee at Home Technologies in Newport News, Virginia, was walking her employer's Westie around the Center's manmade lake on Thursday when she saw a large, mysterious blob floating in the water.
Co-worker Charlie Schmuck says "The lake is behind our office. Tracy was walking by the lake, saw the object, and asked everyone else to come out and take a look."
Tracy thought it was "a huge dead snake."
Charlie thought it "looked like some weird underwater fungus, like the ones that explode when you poke them."
Perhaps because it was just a few days ...
ACP's response to the IOM's report the future of nursing: Leading change, advancing health
2010-11-02
The Institute of Medicine (IOM) recently released a study, The Future of Nursing: Leading Change, Advancing Health. The report calls for new and expanded roles for nurses in a redesigned health care system. It recommends improving education for all nurses and allowing nurses to practice to the full extent of their license and ability. It advocates overhauling state scope of practice acts and suggests that advanced practice registered nurses (APRNs) -- certified registered nurse anesthetists, certified nurse-midwives, clinical nurse specialists, and certified nurse practitioners ...
Autism Consortium 2010 Symposium: New therapeutics focus, family resource guide announced
2010-11-02
Boston – November 1, 2010 – The Autism Consortium, an innovative Boston area collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), announced that it will begin a new initiative on Translational Medicine and Autism Therapeutics. The new focus was introduced at the Consortium's fifth annual symposium held October 26th, 2010, at Harvard Medical School in Boston.
"As scientists are starting to connect genetics to brain function and behavior, we believe it is time ...
Grasses have potential as alternate ethanol crop, Illinois study finds
2010-11-02
CHAMPAIGN, Ill. — Money may not grow on trees, but energy could grow in grass. Researchers at the University of Illinois have completed the first extensive geographic yield and economic analysis of potential bioenergy grass crops in the Midwestern United States.
Demand for biofuels is increasing as Americans seek to expand renewable energy sources and mitigate the effects of fluctuating energy prices. Corn ethanol is the main biofuel on the market, but demand for ethanol competes with corn's availability as a food, and rising ethanol consumption could lead to higher food ...
Of 50,000 small molecules tested to fight cancer, 2 show promise
2010-11-02
BOSTON (3:00 p.m. ET, November 1, 2010) — A class of compounds that interferes with cell signaling pathways may provide a new approach to cancer treatment, according to a study published online this week in the Proceedings of the National Academy of Sciences (PNAS) Early Edition. The compounds, called PITs (non-phosphoinositide PIP3 inhibitors), limited tumor growth in mice by inducing cell death.
"PITs cause cells to self-destruct by interfering with the signaling pathways that regulate cell survival. As compounds that promote cell death, PITs show promise in halting ...
Anger makes people want things more
2010-11-02
Anger is an interesting emotion for psychologists. On the one hand, it's negative, but then it also has some of the features of positive emotions. For a new study published in Psychological Science, a journal of the Association for Psychological Science, researchers find that associating an object with anger actually makes people want the object—a kind of motivation that's normally associated with positive emotions.
People usually think of anger as a negative emotion. You're not supposed to get angry. But anger also has some positive features. For example, it activates ...
New way of removing excess nitrogen from the environment
2010-11-02
Excess nitrogen from agricultural and urban lands is contaminating groundwater, streams, lakes and estuaries, where it causes harmful algal blooms and contributes to fish kills.
Cost-effective approaches to removing this nitrogen from croplands and urban stormwater runoff before it reaches sensitive water bodies have been elusive.
But simple and inexpensive technologies are on the horizon. A recent scientific workshop on denitrification brought together ecologists, engineers and policy experts to find answers.
Denitrification is a biological process carried out by ...
NYU Courant researchers develop algebraic model to monitor cellular change
2010-11-02
Researchers at New York University's Courant Institute of Mathematical Sciences have developed a novel algebraic model of DNA "hybridization," a process central to most biotechnology devices that monitor changes in cell's gene expression or characterize a cell's genome. Their work, which is described in the journal Physical Review E, provides an additional tool for understanding how biological systems function and could enhance methods and designs of technologies used in cancer and genetics research.
Biology researchers seek to measure cell activity, but the task is a ...
Lead poisoning maps in R.I. reveal huge disparities, guide cleanup
2010-11-02
PROVIDENCE, R.I. [Brown University] — The rate at which lead poisoning has struck young Rhode Island children depends heavily on where they live, according to a Brown University-led geographic analysis of comprehensive health department data from across Rhode Island between 1993 and 2005. By mapping cases of lead poisoning, researchers have been able to help target cleanup resources to do the most good.
During that 12-year period, some census blocks in the state had no cases of poisoning in the study group of 204,746 children, but in the hardest hit census blocks of Providence, ...
LAST 30 PRESS RELEASES:
Advancing personalized medicine through pharmacogenomics: Insights from Ochsner Health
Researchers tested an asthma drug for treating alcoholism. It failed except with this group
Set it and forget it: Autonomous structures can be programmed to jump days in advance
Iron from coal, steel industries alters North Pacific ecosystem
Canadian researcher receives funding from ARIA to unlock potential of plants
Visionary support from Veale Foundation will establish university hospitals Veale Healthcare Transformation Institute
Investigating cocaine addiction using fruit flies
Fruit flies on cocaine could reveal better therapies for addiction
New data shows MMR vaccination rate decline across US
Clinical validation of a circulating tumor DNA–based blood test to screen for colorectal cancer
Screening colonoscopy yields among adults ages 45 to 49 after lowering the colon cancer screening age
Trends in county-level MMR vaccination coverage in children in the United States
Brewed for longevity: drinking coffee linked with healthy aging in women
Researchers find early driver of prostate cancer aggressiveness
Insect protein blocks bacterial infection
New study casts doubt on the likelihood of a Milky Way – Andromeda collision
Prevalence of artificial sweetener neotame in U.S.-marketed disposable e-cigarettes
E-cigarette warnings lower vaping interest and raise quit intentions
Record high: Study finds growing cannabis use among older adults
Trends in past-month cannabis use among older adults
How to create aqueous 100 nm-sized materials with polycavities
Epilepsy is more common in patients with frontotemporal dementia than expected
Pre-operative THP leads to a pCR in two-thirds of early-stage HER2+ ER- breast cancer patients
Immune system discovery reveals potential solution to Alzheimer’s
Salamanders suffering from rising temperatures
It’s not too late to start eating better for your brain
Study finds seniors are money savvy – until dementia sets in
Synthetic compound shows promise against multidrug resistance
Researchers recreate ancient Egyptian blues
Immunotherapy before surgery improves lung cancer survival in global clinical trial led by Irish cancer specialist
[Press-News.org] A discovery could be important for the therapy of lymphoma and leukemiaThe IRCM's Dr. Javier M. Di Noia identifies a mechanism regulating activation-induced deaminase